Optional Technical Trial definition

Optional Technical Trial means the trial to be conducted during Wave 1 to verify the capability of the DER Unit to provide Reactive Power Response in response to network conditions, taking place during the times outlined in the Market Trial Calendar;
Sample 1Sample 2Sample 3
Optional Technical Trial has the meaning given to it in schedule 2
Sample 1

Examples of Optional Technical Trial in a sentence

  • We will work with DER to schedule these as soon as possible to maximise a DER chances of maximising their Participation Payments for Optional Technical Trial.

  • During the Mandatory Technical Trial DER will receive an administered Utilisation Price set to £150/MWh There will be no Optional Technical Trial for the Active Power Service in Wave 1.

  • Before a DER can participate in the Optional Technical Trial (which participation payments are linked to, see below) it must first complete a period of Mandatory Technical Trials (for which no payments are made to a DERs).

  • During the Commissioning active power service test, DER will receive an administered Utilisation Price set to £150/MWh.There will be no Optional Technical Trial for the Active Power Service in wave 1.

  • Participation Payments will be made on a per site basis, split across the two Wave 1 Optional Technical Trial periods (the Winter Trial and the Summer Trial) and linked to Reactive Power Availability during these periods.

  • Of the total available Participation Payment payable: • [75%] will be payable for the Optional Technical Trial in the Wave 1 Winter Trial Period; and 4 DER that cannot carry out Mandatory Technical Trials in the first two weeks of the trial will not be able to offer availability for Optional Technical Trials until they have completed their Mandatory Technical Trials.

  • Any DER who joins the project partway through the trial must complete their Mandatory Technical Trials (to be scheduled with the DER) before being eligible to recover Participation Payments for Wave 1 or Market Revenues for Wave 2 or Wave 3 • [25%] will be payable for the Optional Technical Trial in the Wave 1 Summer Trial Period.

  • The Provider shall be entitled in the Wave 1 Optional Technical Trial to Participation Payments calculated in accordance with Schedule 2 (Payments) by reference to the aggregate number of hours in which the DER Unit was made Available in accordance with a Voltage Arming Instruction, excluding any Settlement Period in which an Availability Failure occurred.

  • Davis believed he was copying these files as a standard practice, believed the Library to have full access to all files he copied, and thus did not consider them Government property as described by the certification.

  • We will work with DER to schedule these as soon as possible to maximise a DER’s chances of maximising their Participation Payments for Optional Technical Trial.

Related to Optional Technical Trial

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Clinical Trial means any human clinical trial of a Product.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Development Phase means the period before a vehicle type is type approved.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Research Program has the meaning set forth in Section 3.1.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Licensed Program means the executable processing programs of licensed information, which is composed of various modules in the Licensed Software package provided by the Licensor.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Development Program means the implementation of the development plan.

  • Research License means a nontransferable, nonexclusive license to make and to use the Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.